Menu Menu
News

Taskforce notes TGA provisional approval for Evusheld

25 February, 2022

The Taskforce notes that on Friday, February 24, 2022, the Therapeutic Goods Administration (TGA) granted provisional approval for tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis (prevention).

Taskforce guidance on the use of Evusheld will be published early next week.

Ends.

 

Topics